Healthcare >> Analyst Interviews >> February 14, 2005
DAVID RISINGER joined Merrill Lynch in July 1999 as a First Vice
President responsible for coverage of the Healthcare Information
Technology and Distribution sector. In November 2002, he assumed
coverage of US major pharmaceuticals. Mr. Risinger covers the US
pharmaceutical industry for Merrill Lynch's Equity Research Department
in the United States. In 2004, he was ranked a 'Runner Up' in the US
Major Pharmaceutical category of the Institutional Investor poll. Prior
to joining Merrill Lynch as a First Vice President, he spent eight years
in pharmaceutical and healthcare equity research at Morgan Stanley and
Dillon Read. Mr. Risinger was a top-ranked healthcare distribution and
IT analyst in the Institutional Investor poll in 2000, 2001 and 2002.
In 1998 and 1999, he was ranked in the Reuters Survey for his research
in the healthcare industry. Mr. Risinger graduated from Bucknell
University in 1991 with a BA in Political Science and received his CFA
Charter in 1995. Profile
from your perspective?
Mr. Risinger: The number one issue is litigation. There are a number of
binary events that are
